Bleakley Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bleakley Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,014	Closed	-$330K	–	565
2024 Q4	$330K	Buy	+5,014	New	+$336K	0.01%	763
2024 Q3	–	Sell	-2,548	Closed	-$210K	–	1032
2024 Q2	$210K	Sell	2,548 -410	-14%	-$34.1K	0.01%	881
2024 Q1	$258K	Sell	2,958 -104	-3%	-$9.31K	0.01%	807
2023 Q4	$295K	Buy	3,062 +91	+3%	+$8.05K	0.01%	740
2023 Q3	$263K	Buy	2,971 +228	+8%	+$20.3K	0.01%	721
2023 Q2	$238K	Buy	2,743 +83	+3%	+$7.81K	0.01%	796
2023 Q1	$259K	Sell	2,660 -13,125	-83%	-$1.36M	0.01%	748
2022 Q4	$1.63M	Buy	+15,785	New	+$1.48M	0.06%	295

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bleakley Financial Group's BMRN Position: Q1 2025 in Review

Bleakley Financial Group sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 5,014 shares — an estimated $330K sold.

Bleakley Financial Group first reported a position in BMRN in Q4 2022 and held it in 8 quarters. The position peaked at $1.63M in Q4 2022. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

Bleakley Financial Group reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Bleakley Financial Group sold 5,014 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $330K.
Bleakley Financial Group first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 8 quarters.
Bleakley Financial Group's BioMarin Pharmaceuticals position peaked at $1.63M in Q4 2022.
584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Bleakley Financial Group's 13F filing for Q1 2025, filed 1 May 2025.